MA53481A - Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde - Google Patents
Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïdeInfo
- Publication number
- MA53481A MA53481A MA053481A MA53481A MA53481A MA 53481 A MA53481 A MA 53481A MA 053481 A MA053481 A MA 053481A MA 53481 A MA53481 A MA 53481A MA 53481 A MA53481 A MA 53481A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- rheumatoid arthritis
- treating subjects
- subjects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Rehabilitation Therapy (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862724212P | 2018-08-29 | 2018-08-29 | |
US201862747301P | 2018-10-18 | 2018-10-18 | |
US201962798697P | 2019-01-30 | 2019-01-30 | |
US201962824399P | 2019-03-27 | 2019-03-27 | |
US201962856431P | 2019-06-03 | 2019-06-03 | |
US201962858443P | 2019-06-07 | 2019-06-07 | |
EP19192387 | 2019-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53481A true MA53481A (fr) | 2021-07-07 |
Family
ID=67851236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053481A MA53481A (fr) | 2018-08-29 | 2019-08-28 | Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde |
Country Status (16)
Country | Link |
---|---|
US (2) | US11319375B2 (fr) |
EP (1) | EP3843852A1 (fr) |
JP (1) | JP7504871B2 (fr) |
KR (1) | KR20210049871A (fr) |
CN (1) | CN112955222A (fr) |
AU (1) | AU2019329958A1 (fr) |
BR (1) | BR112021003206A2 (fr) |
CA (1) | CA3110891A1 (fr) |
CL (1) | CL2021000483A1 (fr) |
IL (1) | IL280824A (fr) |
MA (1) | MA53481A (fr) |
MX (1) | MX2021002422A (fr) |
PH (1) | PH12021550416A1 (fr) |
SG (1) | SG11202101674QA (fr) |
TW (1) | TW202026035A (fr) |
WO (1) | WO2020047029A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023527059A (ja) * | 2020-05-26 | 2023-06-26 | サノフィ・バイオテクノロジー | 関節リウマチを治療するためのインターロイキン6受容体に対する抗体を含む組成物およびその使用方法 |
KR20230031015A (ko) * | 2021-08-26 | 2023-03-07 | 주식회사 이뮨메드 | 자가면역질환의 예방 또는 치료를 위한 항체의약품 |
CN117138126B (zh) * | 2023-08-30 | 2024-04-09 | 江苏恰瑞生物科技有限公司 | 定向清除炎症因子il-6的过滤材料及过滤柱 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5171840A (en) | 1988-01-22 | 1992-12-15 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
ES2156859T5 (es) | 1991-03-18 | 2008-03-16 | New York University | Anticuerpos monoclonales y quimericos especificos para el factor de necrosis tumoral humano. |
US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
US5215534A (en) | 1991-12-02 | 1993-06-01 | Lawrence De Harde | Safety syringe system |
WO1994006476A1 (fr) | 1992-09-15 | 1994-03-31 | Immunex Corporation | Procede de traitement de l'inflammation dependante du facteur necrosant des tumeurs malignes (tnf) a l'aide d'antagonistes dudit tnf |
PT783893E (pt) | 1994-10-07 | 2012-05-24 | Chugai Pharmaceutical Co Ltd | Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo |
PL187733B1 (pl) | 1996-02-26 | 2004-09-30 | Advanced Res & Tech Inst | Zastosowanie inhibitora anhydrazy węglanowej |
US6670373B1 (en) | 1999-10-07 | 2003-12-30 | Eli Lilly And Company | Compounds and method for inhibiting MRP1 |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CA2868614A1 (fr) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methodes pour administrer des anticorps anti-tnf.alpha. |
WO2004091657A2 (fr) | 2003-04-09 | 2004-10-28 | Genentech, Inc. | Traitement d'une maladie auto-immune chez un patient presentant une reponse inadequate a un inhibiteur de tnf-$g(a) |
CA2565714C (fr) | 2004-05-06 | 2014-12-23 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Processus et compositions pour le traitement de l'uveite |
KR20070047327A (ko) | 2004-07-26 | 2007-05-04 | 비오겐 아이덱 엠에이 아이엔씨. | 항-cd154 항체 |
PT1963368E (pt) | 2005-12-13 | 2012-09-14 | Lilly Co Eli | Anticorpos anti-il-17 |
US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
PL2041177T3 (pl) | 2006-06-02 | 2012-09-28 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
FR2920033B1 (fr) | 2007-08-13 | 2014-08-22 | Snecma | Turbomachine avec diffuseur |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
SG10201703707YA (en) | 2009-03-19 | 2017-06-29 | Chugai Pharmaceutical Co Ltd | Pharmaceutical formulation containing improved antibody molecules |
JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
WO2011006273A1 (fr) * | 2009-07-15 | 2011-01-20 | Eva Kovacs-Benke | Combinaison d'un antagoniste de l'interleukine-6 humaine et d'un antagoniste du récepteur de l'interleukine-6 humaine dans une thérapie contre des maladies tumorales |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
BR112012028557A2 (pt) | 2010-05-07 | 2019-09-24 | Xoma Technology Ltd. | uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo. |
US9427531B2 (en) | 2010-06-28 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Auto-injector |
US20140017261A1 (en) | 2011-02-03 | 2014-01-16 | Mark Totoritis | Selection and treatment of subjects |
TWI568888B (zh) | 2011-09-15 | 2017-02-01 | 第諾拉工業公司 | 氣體擴散電極及其製法和電化電解池 |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US9248242B2 (en) | 2012-04-20 | 2016-02-02 | Safety Syringes, Inc. | Anti-needle stick safety device for injection device |
EP3042202A1 (fr) * | 2013-09-03 | 2016-07-13 | Graham, L. Douglas | Procédés de traitement de la polyarthrite rhumatoïde |
US20160280782A1 (en) | 2013-11-22 | 2016-09-29 | Sanofi Biotechnology | Compositions for the treatment of rheumatoid arthritis and methods of using same |
WO2015116852A1 (fr) * | 2014-01-29 | 2015-08-06 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de la polyarthrite rhumatoïde par l'administration d'un anticorps anti il-6r |
US20170252434A1 (en) | 2014-09-16 | 2017-09-07 | Sanofi Biotechnology | Compositions for improving the health related quality of life of rheumatoid arthritis patients |
AU2016348418B8 (en) | 2015-11-03 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same |
KR20180114955A (ko) | 2016-03-07 | 2018-10-19 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 류마티스 관절염의 치료를 위한 조성물 및 방법 |
-
2019
- 2019-08-28 MX MX2021002422A patent/MX2021002422A/es unknown
- 2019-08-28 BR BR112021003206-1A patent/BR112021003206A2/pt unknown
- 2019-08-28 US US16/553,338 patent/US11319375B2/en active Active
- 2019-08-28 KR KR1020217008732A patent/KR20210049871A/ko unknown
- 2019-08-28 JP JP2021510860A patent/JP7504871B2/ja active Active
- 2019-08-28 CA CA3110891A patent/CA3110891A1/fr active Pending
- 2019-08-28 SG SG11202101674QA patent/SG11202101674QA/en unknown
- 2019-08-28 EP EP19763150.0A patent/EP3843852A1/fr active Pending
- 2019-08-28 TW TW108130759A patent/TW202026035A/zh unknown
- 2019-08-28 WO PCT/US2019/048460 patent/WO2020047029A1/fr unknown
- 2019-08-28 AU AU2019329958A patent/AU2019329958A1/en active Pending
- 2019-08-28 MA MA053481A patent/MA53481A/fr unknown
- 2019-08-28 CN CN201980065880.1A patent/CN112955222A/zh active Pending
-
2021
- 2021-02-11 IL IL280824A patent/IL280824A/en unknown
- 2021-02-25 CL CL2021000483A patent/CL2021000483A1/es unknown
- 2021-02-26 PH PH12021550416A patent/PH12021550416A1/en unknown
-
2022
- 2022-03-23 US US17/701,748 patent/US20230059376A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2021002422A (es) | 2021-07-15 |
US20230059376A1 (en) | 2023-02-23 |
WO2020047029A1 (fr) | 2020-03-05 |
TW202026035A (zh) | 2020-07-16 |
PH12021550416A1 (en) | 2021-09-27 |
JP7504871B2 (ja) | 2024-06-24 |
KR20210049871A (ko) | 2021-05-06 |
JP2022502350A (ja) | 2022-01-11 |
CL2021000483A1 (es) | 2021-07-19 |
US11319375B2 (en) | 2022-05-03 |
IL280824A (en) | 2021-04-29 |
US20200102395A1 (en) | 2020-04-02 |
CN112955222A (zh) | 2021-06-11 |
SG11202101674QA (en) | 2021-03-30 |
CA3110891A1 (fr) | 2020-03-05 |
EP3843852A1 (fr) | 2021-07-07 |
AU2019329958A1 (en) | 2021-03-18 |
BR112021003206A2 (pt) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
MA50082A (fr) | Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer | |
MA52780A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
MA52564A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA43640A (fr) | Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MA40867A (fr) | Méthodes pour le traitement d'infections virales à filoviridae | |
MA41028A (fr) | Méthodes et formulations pour le traitement de pathologies oculaires vasculaires | |
MA52371A (fr) | Méthodes de traitement d'infections dues aux coronaviridae | |
MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
MA46836A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
MA56212A (fr) | Compositions et méthodes de traitement du cancer | |
MA53481A (fr) | Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde | |
MA41119A (fr) | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique | |
MA43982A (fr) | Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1 | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
MA45675A (fr) | Méthodes et compositions permettant le traitement du cancer |